The third targeted therapy group documented in our study was the ICI group, which in most cases, was atezolizumab, which has been approved for the therapy of triple-negative (HR–/HER2–) metastasized or locally advanced unresectable breast cancer with PD-L1 expression ≥1% [21]. Here, ERBB2 is linked to breast carcinoma.